Oral probiotic combination of Lactobacillus and Bifidobacterium alters the gastrointestinal microbiota during antibiotic treatment for Clostridium difficile infection

Autor: Nasia Safdar, Shoshannah Eggers, Kimberly A. Dill-McFarland, Anna K. Barker, T. J. De Wolfe, Ashley E. Kates, Garret Suen
Jazyk: angličtina
Rok vydání: 2018
Předmět:
0301 basic medicine
Administration
Oral
lcsh:Medicine
law.invention
Probiotic
Lactobacillus acidophilus
law
Antibiotics
Lactobacillus
Ruminococcus
Medicine and Health Sciences
Medicine
Bacteroides
lcsh:Science
Bifidobacterium
Data Management
Multidisciplinary
biology
Antimicrobials
Gastrointestinal Microbiome
Drugs
Genomics
3. Good health
Anti-Bacterial Agents
Medical Microbiology
Research Design
Antibiotic transport
Research Article
Microbial Taxonomy
Computer and Information Sciences
Lactobacillus paracasei
Clostridium Difficile
Clinical Research Design
Microbial Genomics
Research and Analysis Methods
Microbiology
03 medical and health sciences
Microbial Control
Genetics
Humans
Microbiome
Taxonomy
Pharmacology
Bacteria
business.industry
Probiotics
Gut Bacteria
lcsh:R
Organisms
Biology and Life Sciences
biology.organism_classification
030104 developmental biology
Clostridium Infections
lcsh:Q
business
Zdroj: PLoS ONE, Vol 13, Iss 9, p e0204253 (2018)
PLoS ONE
ISSN: 1932-6203
Popis: Perturbations in the gastrointestinal microbiome caused by antibiotics are a major risk factor for Clostridium difficile infection (CDI). Probiotics are often recommended to mitigate CDI symptoms; however, there exists only limited evidence showing probiotic efficacy for CDI. Here, we examined changes to the GI microbiota in a study population where probiotic treatment was associated with significantly reduced duration of CDI diarrhea. Subjects being treated with standard of care antibiotics for a primary episode of CDI were randomized to probiotic treatment or placebo for 4 weeks. Probiotic treatment consisted of a daily multi-strain capsule (Lactobacillus acidophilus NCFM, ATCC 700396; Lactobacillus paracasei Lpc-37, ATCC SD5275; Bifidobacterium lactis Bi-07, ATCC SC5220; Bifidobacterium lactis B1-04, ATCC SD5219) containing 1.7 x 1010 CFUs. Stool was collected and analyzed using 16S rRNA sequencing. Microbiome analysis revealed apparent taxonomic differences between treatments and timepoints. Subjects administered probiotics had reduced Verrucomicrobiaceae at week 8 compared to controls. Bacteroides were significantly reduced between weeks 0 to 4 in probiotic treated subjects. Ruminococcus (family Lachnospiraceae), tended to be more abundant at week 8 than week 4 within the placebo group and at week 8 than week 0 within the probiotic group. Similar to these results, previous studies have associated these taxa with probiotic use and with mitigation of CDI symptoms. Compositional prediction of microbial community function revealed that subjects in the placebo group had microbiomes enriched with the iron complex transport system, while probiotic treated subjects had microbiomes enriched with the antibiotic transport system. Results indicate that probiotic use may impact the microbiome function in the face of a CDI; yet, more sensitive methods with higher resolution are warranted to better elucidate the roles associated with these changes. Continuing studies are needed to better understand probiotic effects on microbiome structure and function and the resulting impacts on CDI.
Databáze: OpenAIRE
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje